Diacylglycerol O-acyltransferase 2 (DGAT2) inhibitors are promising ones aimed at the treatment of metabolic disorders, particularly non-alcoholic steatohepatitis, type 2 diabetes, and hyperlipidemia. Here, DGAT2 is linked to metabolic dysfunction-associated steatohepatitis.